ENTA
Price
$4.85
Change
-$0.18 (-3.58%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
102.58M
22 days until earnings call
KROS
Price
$12.52
Change
-$0.30 (-2.34%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
505.53M
44 days until earnings call
Ad is loading...

ENTA vs KROS

Header iconENTA vs KROS Comparison
Open Charts ENTA vs KROSBanner chart's image
Enanta Pharmaceuticals
Price$4.85
Change-$0.18 (-3.58%)
Volume$26.91K
Capitalization102.58M
Keros Therapeutics
Price$12.52
Change-$0.30 (-2.34%)
Volume$21.64K
Capitalization505.53M
ENTA vs KROS Comparison Chart
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. KROS commentary
Jan 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and KROS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 15, 2025
Stock price -- (ENTA: $4.84 vs. KROS: $12.48)
Brand notoriety: ENTA and KROS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 114% vs. KROS: 91%
Market capitalization -- ENTA: $102.58M vs. KROS: $505.53M
ENTA [@Biotechnology] is valued at $102.58M. KROS’s [@Biotechnology] market capitalization is $505.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $374.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileKROS’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • KROS’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 5 TA indicator(s) are bullish while KROS’s TA Score has 3 bullish TA indicator(s).

  • ENTA’s TA Score: 5 bullish, 2 bearish.
  • KROS’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than KROS.

Price Growth

ENTA (@Biotechnology) experienced а -10.20% price change this week, while KROS (@Biotechnology) price change was -21.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.85%. For the same industry, the average monthly price growth was -2.06%, and the average quarterly price growth was -3.70%.

Reported Earning Dates

ENTA is expected to report earnings on May 12, 2025.

KROS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-6.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KROS($506M) has a higher market cap than ENTA($103M). ENTA YTD gains are higher at: -12.522 vs. KROS (-19.015). ENTA has higher annual earnings (EBITDA): -104.51M vs. KROS (-185.94M). KROS has more cash in the bank: 531M vs. ENTA (248M). KROS has less debt than ENTA: KROS (19.3M) vs ENTA (55.5M). ENTA has higher revenues than KROS: ENTA (67.6M) vs KROS (651K).
ENTAKROSENTA / KROS
Capitalization103M506M20%
EBITDA-104.51M-185.94M56%
Gain YTD-12.522-19.01566%
P/E RatioN/AN/A-
Revenue67.6M651K10,384%
Total Cash248M531M47%
Total Debt55.5M19.3M288%
FUNDAMENTALS RATINGS
ENTA: Fundamental Ratings
ENTA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
96
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ENTAKROS
RSI
ODDS (%)
Bullish Trend 7 days ago
61%
N/A
Stochastic
ODDS (%)
Bullish Trend 7 days ago
66%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bullish Trend 7 days ago
87%
Bullish Trend 7 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 7 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 7 days ago
85%
Advances
ODDS (%)
Bullish Trend 23 days ago
71%
Bullish Trend 12 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
83%
Bearish Trend 16 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
77%
Bullish Trend 7 days ago
79%
Aroon
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
85%
View a ticker or compare two or three
Ad is loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KROS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LDNXF143.00N/A
N/A
London Stock Exchange Ltd.
NWBO0.27N/A
-0.06%
Northwest Biotherapeutics, Inc.
OLYMY14.52-0.01
-0.07%
Olympus Corp.
SKFRY18.68-0.30
-1.58%
AB SKF
SUUFF0.12-0.01
-6.82%
STRATHMORE PLUS URANIUM CORP.

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with CLRB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-1.18%
CLRB - ENTA
40%
Loosely correlated
-0.18%
INZY - ENTA
40%
Loosely correlated
-13.78%
ETNB - ENTA
39%
Loosely correlated
-3.07%
AURA - ENTA
38%
Loosely correlated
-1.32%
IDYA - ENTA
37%
Loosely correlated
-4.41%
More

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with INZY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
-11.95%
INZY - KROS
43%
Loosely correlated
-13.78%
AXON - KROS
43%
Loosely correlated
-0.23%
TFFP - KROS
41%
Loosely correlated
N/A
XENE - KROS
40%
Loosely correlated
-0.42%
RAPT - KROS
39%
Loosely correlated
-8.33%
More